Clinical Trials

For individuals with ALS, a daily dosing regimen of oral edaravone was nonsuperior to an FDA-approved staggered regimen of the drug plus placebo, according to a poster presented at AANEM.

Treatment with oral blarcamesine for older adults with Alzheimer’s disease led to significant slowing of clinical decline compared with placebo at 48 weeks, according to new research presented at CTAD.

Amy Hajari Case, MD, FCCP, has been named chief medical officer of the Pulmonary Fibrosis Foundation, according to a press release.

An oral therapeutic significantly reduced the number of tumors in adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas, according to topline results from a phase 3 study.

IV administration of Uplizna was safe and shown to be more efficacious for those with generalized myasthenia gravis compared with placebo at week 26, according to a presentation from AANEM.

IV administration of fasudil at two separate doses was safe and well tolerated in a small cohort of individuals with suspected or confirmed ALS, according to new research published in The Lancet.

CHICAGO — In this video, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses highlights from the AAO meeting.

Treatment with non-invasive, personalized repetitive transcranial magnetic stimulation in those with mild to moderate Alzheimer’s resulted in a 44% slowing of disease progression at 52 weeks, according to the manufacturer.

Most counties in the United States do not have active cancer clinical trials, according to results of an ASCO analysis.

The European Medicines Agency has granted orphan drug designation to a small molecule intended to treat spinal and bulbar muscular atrophy, according to the manufacturer.